SG11201706992TA - Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use - Google Patents
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for useInfo
- Publication number
- SG11201706992TA SG11201706992TA SG11201706992TA SG11201706992TA SG11201706992TA SG 11201706992T A SG11201706992T A SG 11201706992TA SG 11201706992T A SG11201706992T A SG 11201706992TA SG 11201706992T A SG11201706992T A SG 11201706992TA SG 11201706992T A SG11201706992T A SG 11201706992TA
- Authority
- SG
- Singapore
- Prior art keywords
- novel
- methods
- pharmaceutical compositions
- substituted derivatives
- indol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2015/051957 WO2015140717A1 (fr) | 2014-03-18 | 2015-03-17 | Dérivés substitués par 3-indole, compositions pharmaceutiques et procédés d'utilisation |
| US201562203032P | 2015-08-10 | 2015-08-10 | |
| PCT/IB2016/051509 WO2016147144A1 (fr) | 2015-03-17 | 2016-03-17 | Nouveaux dérivés substitués par un 2-indole, compositions pharmaceutiques et leurs procédés d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706992TA true SG11201706992TA (en) | 2017-09-28 |
Family
ID=56919874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706992TA SG11201706992TA (en) | 2015-03-17 | 2016-03-17 | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9873690B2 (fr) |
| EP (1) | EP3271354A1 (fr) |
| JP (1) | JP6775516B2 (fr) |
| KR (1) | KR102013512B1 (fr) |
| CN (1) | CN107635990A (fr) |
| AU (1) | AU2016231832B2 (fr) |
| BR (1) | BR112017019699A2 (fr) |
| CA (1) | CA2979616C (fr) |
| HK (1) | HK1243999A1 (fr) |
| IL (1) | IL254124A0 (fr) |
| MX (1) | MX2017011951A (fr) |
| RU (1) | RU2672252C1 (fr) |
| SG (1) | SG11201706992TA (fr) |
| WO (1) | WO2016147144A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160336813A1 (en) | 2015-05-15 | 2016-11-17 | NeuSpera Medical Inc. | Midfield coupler |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3554494A4 (fr) | 2016-12-19 | 2021-02-17 | Cellixbio Private Limited | Compositions et méthodes pour le traitement d'une inflammation |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| CA3060989A1 (fr) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprenant une combinaison d'un anticorps anti-lag-3, d'un inhibiteur de voie pd-1 et d'un agent immunotherapeutique |
| SG11202003341UA (en) | 2017-10-13 | 2020-05-28 | Harpoon Therapeutics Inc | B cell maturation antigen binding proteins |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| WO2021024020A1 (fr) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer |
| CN111166735B (zh) * | 2020-01-15 | 2023-08-18 | 延边大学 | 邻苯二甲酸-双-(2-乙基庚基)酯在抑制脂肪蓄积中的应用 |
| CN111499592B (zh) * | 2020-03-14 | 2023-06-23 | 江苏省农用激素工程技术研究中心有限公司 | 5-氨甲基糖精的合成方法 |
| KR102574950B1 (ko) | 2020-04-30 | 2023-09-06 | 메드샤인 디스커버리 아이엔씨. | 벤조술탐 함유 화합물 |
| CN116234568A (zh) | 2020-07-07 | 2023-06-06 | 生物技术公司 | 用于hpv阳性癌症的治疗性rna |
| CN111777557B (zh) * | 2020-07-28 | 2022-11-22 | 中国科学院上海有机化学研究所 | 以芳香联苯烯为骨架的新型抗肿瘤先导化合物及其应用 |
| WO2022135666A1 (fr) | 2020-12-21 | 2022-06-30 | BioNTech SE | Programme de traitement faisant intervenir des protéines cytokines |
| WO2022135667A1 (fr) | 2020-12-21 | 2022-06-30 | BioNTech SE | Arn thérapeutique pour le traitement du cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023170606A1 (fr) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Utilisation d'anticorps anti-claudine-1 pour augmenter la disponibilité des lymphocytes t |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509731C2 (sv) | 1996-05-14 | 1999-03-01 | Labwell Ab | Metod för palladium-katalyserade organiska reaktioner innefattande ett uppvärmningssteg utfört med mikrovågsenergi |
| JP2000095759A (ja) | 1998-07-21 | 2000-04-04 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および剤 |
| US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
| EP1427707A1 (fr) | 2001-09-19 | 2004-06-16 | Pharmacia Corporation | Composes d'indazole substitues destines au traitement de l'inflammation |
| WO2003082869A1 (fr) | 2002-03-28 | 2003-10-09 | Eisai Co., Ltd. | Azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| FR2845996A1 (fr) | 2002-10-16 | 2004-04-23 | Servier Lab | Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2006521377A (ja) * | 2003-03-27 | 2006-09-21 | ランケナー インスティテュート フォー メディカル リサーチ | 新型ｉｄｏ阻害剤とその使用方法 |
| CN101265254A (zh) * | 2003-03-27 | 2008-09-17 | 兰肯瑙医学研究所 | 新型ido抑制剂及其使用方法 |
| FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
| GB0328909D0 (en) | 2003-12-12 | 2004-01-14 | Syngenta Participations Ag | Chemical compounds |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| MX2007003336A (es) * | 2004-09-21 | 2007-06-05 | Athersys Inc | Acidos aceticos de indol que muestran antagonismo de receptor crth2 y usos de los mismos. |
| DK1846406T5 (da) | 2005-02-09 | 2011-10-31 | Arqule Inc | Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer |
| WO2007039580A1 (fr) | 2005-10-05 | 2007-04-12 | Nycomed Gmbh | Composes de benzophenone substitues par imidazolyle |
| WO2007045622A1 (fr) | 2005-10-18 | 2007-04-26 | Nycomed Gmbh | Composes oxazolo [4,5-b] pyridine en tant qu’inhibiteurs de l’oxyde nitrique synthetase |
| WO2007050963A1 (fr) * | 2005-10-27 | 2007-05-03 | Lankenau Institute For Medical Research | Nouveaux inhibiteurs de l'ido et leurs procedes d'utilisation |
| CA2637933C (fr) | 2006-01-24 | 2013-03-12 | Eli Lilly And Company | Sulfamide d'indole modulateur de recepteurs de la progesterone |
| MX2008012482A (es) | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
| CA2645633A1 (fr) | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinaisons d'agents therapeutiques pour traiter un cancer |
| GB0624308D0 (en) | 2006-12-05 | 2007-01-17 | Molmed Spa | Combination product |
| BRPI0720049A2 (pt) | 2006-12-07 | 2014-01-07 | Novartis Ag | Derivados de piridina utilizados como inibidores de xiap |
| NZ578744A (en) | 2007-01-31 | 2012-02-24 | Vertex Pharma | 2-aminopyridine derivatives useful as kinase inhibitors |
| US8389568B2 (en) | 2007-03-16 | 2013-03-05 | Lankenau Institute For Medical Research | IDO inhibitors and methods of use thereof |
| CA2694224A1 (fr) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim International Gmbh | Mimetiques de glucocorticoides, leurs procedes de production, compositions pharmaceutiques et utilisations associees |
| US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| JP2011508725A (ja) | 2007-11-30 | 2011-03-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| US8222424B2 (en) | 2008-03-24 | 2012-07-17 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| WO2010008427A1 (fr) | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Catabolisme du tryptophane dans le traitement et le diagnostic du cancer |
| AU2009268739B2 (en) * | 2008-07-08 | 2014-05-08 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| KR20110098827A (ko) | 2008-12-19 | 2011-09-01 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 |
| EP2398810A1 (fr) | 2009-02-17 | 2011-12-28 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la phosphatidylinositol 3-kinase à base de tétrahydrothiazolopyridine |
| CA2772371A1 (fr) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Composes bicycliques indole-pyrimidine inhibiteurs de pi3k selectifs pour p110 delta et leurs procedes d'utilisation |
| KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| US9079904B2 (en) | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
| EP2488030B1 (fr) | 2009-10-12 | 2015-01-07 | Bayer CropScience AG | 1-(pyrid-3-yl)-pyrazoles et 1-(pyrimid-5-yl)-pyrazoles comme moyen de lutte contre les parasites |
| JP5819305B2 (ja) | 2009-10-13 | 2015-11-24 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 造血成長因子模倣小分子化合物およびそれらの使用 |
| EP2642994A2 (fr) | 2010-11-18 | 2013-10-02 | Ligand Pharmaceuticals Incorporated | Utilisation de mimétiques d'un facteur de croissance hématopoïétique |
| EP2688886A1 (fr) | 2011-03-22 | 2014-01-29 | Amgen Inc. | Composés d'azole utilisés en tant qu'inhibiteurs des pim |
| ES2699256T3 (es) | 2011-05-23 | 2019-02-08 | Merck Patent Gmbh | Piridina y derivados de pirazina |
| EP2744805A1 (fr) | 2011-08-17 | 2014-06-25 | Amgen Inc. | Inhibiteurs de canal sodium hétéroaryle |
| US20160263087A1 (en) | 2013-11-08 | 2016-09-15 | Iteos Therapeutics | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9126984B2 (en) | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| CA2939164A1 (fr) | 2014-02-12 | 2015-08-20 | Iteos Therapeutics | Derives de 3-(indol-3-yl)piridine, compositions pharmaceutiques et procedes d'utilisation |
| US20150266857A1 (en) * | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| WO2015140717A1 (fr) | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Dérivés substitués par 3-indole, compositions pharmaceutiques et procédés d'utilisation |
| MD20160118A2 (ro) | 2014-05-15 | 2017-04-30 | Iteos Therapeutics | Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1 |
| CA2994917A1 (fr) * | 2015-08-10 | 2017-02-16 | Pfizer Inc. | Derives substitues par un 3-indole, compositions pharmaceutiques et leurs procedes d'utilisation |
-
2016
- 2016-03-17 US US15/072,534 patent/US9873690B2/en not_active Expired - Fee Related
- 2016-03-17 BR BR112017019699-9A patent/BR112017019699A2/pt not_active Application Discontinuation
- 2016-03-17 RU RU2017130845A patent/RU2672252C1/ru not_active IP Right Cessation
- 2016-03-17 JP JP2017548261A patent/JP6775516B2/ja active Active
- 2016-03-17 SG SG11201706992TA patent/SG11201706992TA/en unknown
- 2016-03-17 MX MX2017011951A patent/MX2017011951A/es unknown
- 2016-03-17 EP EP16711022.0A patent/EP3271354A1/fr not_active Withdrawn
- 2016-03-17 WO PCT/IB2016/051509 patent/WO2016147144A1/fr active Application Filing
- 2016-03-17 AU AU2016231832A patent/AU2016231832B2/en not_active Ceased
- 2016-03-17 KR KR1020177029203A patent/KR102013512B1/ko active IP Right Grant
- 2016-03-17 CN CN201680028408.7A patent/CN107635990A/zh active Pending
- 2016-03-17 CA CA2979616A patent/CA2979616C/fr not_active Expired - Fee Related
-
2017
- 2017-08-23 IL IL254124A patent/IL254124A0/en unknown
-
2018
- 2018-03-12 HK HK18103418.8A patent/HK1243999A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL254124A0 (en) | 2017-10-31 |
| JP6775516B2 (ja) | 2020-10-28 |
| US9873690B2 (en) | 2018-01-23 |
| CA2979616A1 (fr) | 2016-09-22 |
| CN107635990A (zh) | 2018-01-26 |
| KR20170132204A (ko) | 2017-12-01 |
| HK1243999A1 (zh) | 2018-07-27 |
| AU2016231832B2 (en) | 2019-09-19 |
| JP2018511587A (ja) | 2018-04-26 |
| EP3271354A1 (fr) | 2018-01-24 |
| US20160272628A1 (en) | 2016-09-22 |
| WO2016147144A1 (fr) | 2016-09-22 |
| MX2017011951A (es) | 2018-06-15 |
| BR112017019699A2 (pt) | 2018-09-04 |
| CA2979616C (fr) | 2020-04-28 |
| KR102013512B1 (ko) | 2019-08-22 |
| RU2672252C1 (ru) | 2018-11-13 |
| AU2016231832A1 (en) | 2017-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1243999A1 (zh) | 新型3-吲哚取代的衍生物、藥物組合物及使用方法 | |
| IL254714B (en) | History of quinoline and pharmaceutical preparations containing them | |
| IL258082B (en) | History of benzaimidazole and pharmaceutical preparations containing them | |
| IL247062A0 (en) | Heterocyclic compounds, their preparation and pharmaceutical preparations containing them | |
| PT3643709T (pt) | Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos | |
| IL250422B (en) | History of pyrrolidinone, and pharmaceutical preparations containing them | |
| HK1256674A1 (zh) | 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途 | |
| PT3223796T (pt) | Composições farmacêuticas, preparação e suas utilizações | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| IL249308A0 (en) | The history of quinoline, their preparation and pharmaceutical preparations containing them | |
| IL258160B (en) | Biaryl derivatives, pharmaceutical preparations containing them and their uses | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| IL248773B (en) | History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them | |
| IL258977B (en) | Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them | |
| GB201811142D0 (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative | |
| GB201521462D0 (en) | Pharmaceutical composition | |
| PT3229843T (pt) | Composição farmacêutica, a sua preparação e as suas utilizações | |
| EP3284743A4 (fr) | Composés d'imidazole hétérocycliques, compositions pharmaceutiques les contenant, leur procédé de préparation et utilisation | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| IL257621B (en) | A catechol derivative and a pharmaceutical preparation that includes it | |
| HUE053974T2 (hu) | Szemészeti gyógyászati készítmény | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| HK1257129A1 (zh) | 含有吲哚衍生物的藥物組合物、其製備方法和用途 | |
| PL3386988T3 (pl) | Nowe pochodne dihydropiranopirymidynonu i ich zastosowanie | |
| IL259900A (en) | Aminoazole derivatives, compositions containing same and uses thereof |